Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.

Target Audience
The primary target audience for this activity are Academic and community-based physicians and team members, including hematologists, hematologic oncologists, medical oncologists, oncology nurses, NPs, PAs, and hematology-oncology pharmacists.

Statement of Need/Program Overview
Bispecific antibodies are relatively new agents in the treatment of multiple myeloma (MM). Because of this, many oncology clinicians are unfamiliar with their mechanism of action and the adverse events associated with these agents, as well as having limited guidance on appropriate management with these options. Two expert key opinion leaders in MM care will share guidance for clinicians in the community on how to manage transitions of care from academic centers, as well as explore considerations for the inpatient and outpatient setting. The education will also provide insights and best-practice recommendations on appropriate adverse-event management while utilizing bispecific antibodies to manage people with relapsed/refractory MM.

Learning Objectives
After completing this activity, the participant should be better able to:

Apply expert consensus recommendations for adverse-event management related to bispecific antibodies for the treatment of MM
Discuss implications for management at the site of treatment vs follow-up management at a community center
Assess operationalization of team-based adverse-event protocols for patients on bispecific antibodies